Orthocell (ASX:OCC) is on track to meet Euroz Hartley's fiscal 2025 revenue forecast of AU$8.8 million, following positive second-quarter results that met expectations, according to a Wednesday note from the financial services firm.
The company reported a 9% quarter-on-quarter increase in revenue to AU$2.2 million, bringing first-half revenue to AU$4.2 million, up 29% year-on-year, Euroz Hartleys said.
Euroz Hartleys noted that growth was driven by product launches, including Striate+ for dental bone repair and Remplir for nerve repair.
Euroz Hartley believes that the upcoming US FDA approval of Orthocell's Remplir product, expected by April, will be a key catalyst for the company's growth. Approval would allow Remplir to enter the $1.6 billion US nerve repair market, and see a potential increase in the company's share price, it added.
Euroz Hartleys maintained the company's hold rating and its price target of AU$0.97.
Orthocell's shares slipped almost 1% in recent Friday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.